Abbott Laboratories ($ABT) won a CE mark for its FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System, expanding its presence on the European diabetes market with a next-gen device. The latest FreeStyle system allows physicians to program insulin dosage plans into the meter, ideally boosting patient adherence, the company said. Abbott plans to launch the device around the continent in the coming weeks. More